Physician profile
Daniel W Esper
NPI 1053305573
$4,292.93
in general payments reported to CMS, 2019-2025
29 companies · $531 in 2025
The $531 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $372 · 2021: $234 · 2022: $519 · 2023: $877 · 2024: $648 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,055.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,671.26 | 2019-2025 | |
| Abbott Laboratories | $330.36 | 2019-2025 | Mitraclip, Xience Skypoint, Diamondback Coronary |
| Janssen Pharmaceuticals, INC | $278.42 | 2019-2022 | |
| Pfizer INC. | $225.89 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.13 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $198.00 | 2019-2023 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $185.13 | 2023 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $161.67 | 2019-2025 | Wainua, Farxiga |
| Abiomed | $150.34 | 2019-2024 | Impella |
| Chiesi USA, INC. | $141.48 | 2019-2022 | |
| Terumo Medical Corporation | $92.60 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $75.24 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $68.95 | 2019-2022 | |
| Amgen INC. | $64.82 | 2023-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals, Ltd. | $59.56 | 2021-2023 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $49.56 | 2023-2024 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $46.61 | 2024 | Arcalyst |
| Gilead Sciences, INC. | $41.78 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $34.80 | 2023 | Inpefa |
| Boston Scientific Corporation | $27.77 | 2021 | |
| Esperion Therapeutics, INC. | $25.90 | 2022 | |
| Cardinal Health 200 LLC | $25.12 | 2019 | |
| Astellas Pharma US INC | $22.38 | 2019 | |
| Cardiovascular Systems INC. | $19.62 | 2020 | |
| Inari Medical, INC. | $19.55 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Sanofi-Aventis U.S. LLC | $15.80 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $14.89 | 2019 | |
| Edwards Lifesciences Corporation | $12.26 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Esper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.